Align Technology | ALGN - Ebitda

Aktienkurs
157.25
Täglich Wechseln
-3.28 -2.04%
Monatlich
-15.01%
Jährlich
-16.49%
Q2 Prognose
154.09




Ebitda Veränderung Datum
3M USD 1.42B 8M 2026-03
Align Technology USD 260.87M 77.03M 2025-12
Becton, Dickinson and Co. USD 1.71B 433M 2025-12
Bruker USD 110M 101.6M 2026-03
Cardinal Health USD 1.09B 109M 2026-03
Charles River Laboratories USD 229.8M 28.26M 2026-03
Cooper Companies USD 323.4M 13.2M 2025-12
CVS Health USD 5.83B 2.08B 2026-03
Danaher USD 1.92B 204M 2026-03
Dentsply International USD 129M 6M 2026-03
Dexcom USD 364.5M 57.7M 2026-03
Henry Schein USD 289M 2M 2026-03
Idexx Laboratories USD 400.87M 45.95M 2026-03
Insulet USD 181.7M 12.3M 2026-03
Integra LifeSciences USD 76.18M 28.03M 2026-03
IQVIA Holdings USD 932M 114M 2026-03
Masimo USD 85.5M 6.4M 2026-03
McKesson USD 1.88B 206M 2025-12
Mettler Toledo International USD 278.99M 100.24M 2026-03
Revvity USD 272.91M 24M 2026-03
Solventum Corp USD 437M 0 2026-03
Stryker USD 1.57B 618M 2026-03
Teleflex USD 247.07M 575.88M 2025-12
Thermo Fisher Scientific USD 2.7B 464M 2026-03
Veeva Systems USD 374.79M 3.96M 2025-12
Waters USD 380.97M 85.83M 2025-12
Zimmer Biomet Holdings USD 759M 120.8M 2025-12
Zoetis USD 939M 101M 2025-12